Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for neuropathic%20pain returned no results
Showing 31 to 45 of 66 results for neuropathic

  1. Impact of drug-related adverse effects on cost effectiveness and quality of life:- What is the impact of drug-related adverse effects on health economics and quality of life in neuropathic pain?

    of life in neuropathic pain? Any explanatory notes(if applicable) Why this is important:- Pharmacological agents for...

  2. NICE encourages further research into percutaneous electrical nerve stimulation (PENS) for refractory neuropathic pain, particularly to provide more information about selection criteria and long-term outcomes, with clear documentation of the indications for treatment.

    into percutaneous electrical nerve stimulation (PENS) for refractory neuropathic pain, particularly to provide more information about...

  3. Spotlight on valproate prescribing

    also used outside of its product licence (off-label use) for treating neuropathic pain, migraine, depression and dementia. If valproate...

  4. For adults with fibromyalgia or persistent treatment-resistant neuropathic pain, what is the clinical and cost effectiveness of cannabidiol (CBD), containing no, or traces of, delta-9-tetrahydrocannabinol (THC), as an add-on to standard treatment?

    Question For adults with fibromyalgia or persistent treatment-resistant neuropathic pain, what is the clinical and cost effectiveness of...

  5. Carfilzomib for previously treated multiple myeloma (TA657)

    Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults.

  6. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  7. Aptiva for painful diabetic neuropathy (MIB119)

    NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .

  8. Pemetrexed for the treatment of non-small-cell lung cancer (TA124)

    Evidence-based recommendations on pemetrexed for treating non-small-cell lung cancer in adults.

  9. Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain (IPG739)

    Evidence-based recommendations on neurostimulation of lumbar muscles for refractory non-specific chronic low back pain in adults. This involves implanting a pulse generator under the skin of the upper buttock or lower back, which the person can use to manage their pain.

  10. Spinal metastases and metastatic spinal cord compression (NG234)

    This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.

  11. Deep brain stimulation for refractory chronic pain syndromes (excluding headache) (IPG382)

    Evidence-based recommendations on deep brain stimulation for refractory chronic pain syndromes (excluding headache). This involves stimulating a precise area of the brain using an electrode to treat the chronic pain.

  12. Diabetes: annual examination of foot sensation (IND160)

    This indicator covers the percentage of patients with diabetes with a record of testing of foot sensation using a 10 g monofilament within the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM131

  13. Is response to pharmacological treatment predicted more reliably by underlying aetiology or by symptom characteristics?

    certain symptoms that present in healthcare settings, or whether different neuropathic pain conditions with different aetiologies,...

  14. Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain (IPG747)

    Evidence-based recommendations on percutaneous image-guided cryoablation of peripheral neuroma for chronic pain. This involves using a needle-like probe to freeze and destroy small parts of nerves in neuromas to stop the pain signals.

  15. Patient group directions (MPG2)

    This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.